BofA Securities upgraded Bristol Myers Squibb & Co. (NYSE:BMY) , citing near-term catalysts.“What we like about BMY is the valuation coupled with our forecast for a flattish 7-year outlook with risk-adjusted pipeline and favorable mix-related margin tailwinds. When we factor in multiple pipeline-driven upside scenarios (specifically in ’26E), we think the risk-reward is compelling,” analyst Jason Gerberry wrote in an investor note on Monday.BofA upgraded from Neutral to a Buy rating and raised price forecas ...